Even though statins have demonstrated multiple mechanisms by which they might affect tumor cells’ viability, Phase I trial (NCT03560882), a pilot trial of atorvastatin in TP53-mutant and TP53 wild-type malignancies, will determine if atorvastatin will decrease the levels of conformational mutant p53 in solid tumors and relapsed AML. This evidence concerns the gene TP53 and acute myeloid leukemia.